newsfilter
← Latest News
GlobeNewswire·

Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma

  • Immutep presented new survival data from the investigator-initiated EFTISARC-NEO Phase II study at the CTOS 2026 Annual Meeting.
  • The study evaluated eftilagimod alfa (efti) combined with KEYTRUDA (pembrolizumab) & radiotherapy as neoadjuvant treatment for 38 patients with high-risk, resectable soft tissue sarcoma.
  • The latest analysis showed an 81.1% 12-month disease-free survival (DFS) rate, with the 18-month estimate also at 81.1% though follow-up remains ongoing.
  • Patients with post-treatment tumour-infiltrating lymphocyte (TIL) levels above 310 cells/mm² achieved a 95.0% 12-month DFS compared to 64.9% for those with lower levels.
  • Patients with treatment-related hyalinisation & fibrosis greater than 52% had a 93.8% 12-month DFS compared to 71.4% for those with lower levels.
  • No correlation was found between survival outcomes & the presence of tertiary lymphoid structures (TLS) or baseline expression of PD-L1, LAG-3, or TIGIT.
  • Eight patients experienced disease recurrence out of the 38 evaluated at the April 30, 2026 data cut-off.
  • Immutep anticipates reporting additional EFTISARC-NEO data in calendar year 2027.
  • The company plans to advance efti into a registration-directed clinical trial in neoadjuvant soft tissue sarcoma, targeting initiation in the second half of 2027.
Company
Immutep Limited
Keywords
Nasdaq:IMMP, Immutep Limited